Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

Stopped early · Not applicable

Conditions studied: Diabetes Mellitus

In brief

Given the longer half life of insulin degludec compared to glargine /levemir ,investigators believe that insulin degludec will reduce the rate of recurrent DKA. The investigator will randomize participants to control and intervention group. Control group will receive Lantus/Levemir and intervention group will receive degludec. The investigators will call participants monthly and see them in the clinic every three months.The investigators will follow them for 1 year and evaluate if there will be a difference in rate of DKA in between these two groups.

Key facts

Study ID

NCT03001323

Run by

Hennepin Healthcare Research Institute

People needed

27

Starts

2017-01-01

Expected to finish

2020-09-25

Last updated by the study team

2021-05-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients age >18 year with previous diagnosis of Diabetes Mellitus and previous admission for DKA in any facility within the prior 2 years who meet the criteria for DKA at the time of admission and are willing to participate in the study protocol will be enrolled in the study.
• DKA is defined as:
• Serum bicarbonate below 18 mg/dl
• Anion Gap over greater than or equal to 16
• Serum ketones or beta hydroxybutyrate elevation > 3 mmol/L
• Serum glucose greater than or equal to 250 mg/dl

You may not qualify if…

• Patients with no previous DKA, patients who are not willing to consent to participate in the study protocol for 1 year, pregnant women, dementia, and end stage renal disease on dialysis.

Where it is running

• Hennepin County Medical Center — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.